Evidence map›Paper›PMID 41008838›Full record

ArticleCancers2025

Prognostic Role of Kidney Disease in Newly Diagnosed Acute Myeloid Leukemia Under Venetoclax-Based Low-Intensity Therapy.

Katja Krüger, Razif Gabdoulline, Martin Wichmann, Bernhard M W Schmidt, Katharina Götze, Krischan Braitsch, Laura Schmalbrock, Lars Bullinger, Franziska Westendorf, Walter Fiedler and 23 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Katja KrügerDepartment of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany.ORCID 0009-0003-6116-7947
Razif GabdoullineDepartment of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany.ORCID 0000-0002-4780-1134
Martin WichmannDepartment of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany.
Bernhard M W SchmidtDepartment of Nephrology and Hypertension, Hannover Medical School, 30625 Hannover, Germany.ORCID 0000-0002-7351-565X
Katharina GötzeDepartment of Medicine III, School of Medicine and Health, Technical University of Munich (TUM), 81675 Munich, Germany.
Krischan BraitschDepartment of Medicine III, School of Medicine and Health, Technical University of Munich (TUM), 81675 Munich, Germany.
Laura SchmalbrockDepartment of Hematology, Oncology, and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.
Lars BullingerDepartment of Hematology, Oncology, and Cancer Immunology, Campus Benjamin Franklin, Charité-Universitätsmedizin Berlin, 12203 Berlin, Germany.
Franziska WestendorfDepartment of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.ORCID 0000-0002-5897-3310
Walter FiedlerDepartment of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.ORCID 0000-0003-0275-8803
Anke K BergmannDepartment of Human Genetics, Hannover Medical School, 30625 Hannover, Germany.
Jürgen KrauterDepartment of Internal Medicine, Municipal Hospital Braunschweig, 38126 Braunschweig, Germany.
Stephan KaunDepartment of Internal Medicine, Municipal Hospital Bremen-Mitte, 28205 Bremen, Germany.ORCID 0009-0001-7574-2522
Andreas VoßDepartment of Oncology and Hematology, University Clinic Oldenburg, 26133 Oldenburg, Germany.ORCID 0000-0001-9647-5024
Elisabeth Koller3rd Medical Department, Hanusch Hospital, 1140 Vienna, Austria.ORCID 0000-0002-9912-0461
Ulrich GermingDepartment of Hematology, Oncology and Clinical Immunology, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.
Kai WilleUniversity Clinic for Haematology, Oncology, Haemostaseology and Palliative Care Johannes-Wesling-Klinikum Minden, Ruhr-University Bochum, 32429 Minden, Germany.ORCID 0000-0002-7682-8563
Martin GrießhammerUniversity Clinic for Haematology, Oncology, Haemostaseology and Palliative Care Johannes-Wesling-Klinikum Minden, Ruhr-University Bochum, 32429 Minden, Germany.
Jan BraessDepartment of Oncology and Hematology, Hospital Barmherzige Brueder Regensburg, 93049 Regensburg, Germany.
Daniel FöhringEvang. Krankenhaus Essen-Werden, 45239 Essen, Germany.ORCID 0009-0004-3304-6598
Peter ReimerEvang. Krankenhaus Essen-Werden, 45239 Essen, Germany.
Ulrich KaiserMedical Department II, St. Bernwards Hospital, 31134 Hildesheim, Germany.
Heinz KirchenDepartment of Internal Medicine I, Krankenhaus der Barmherzigen Brüder, 54292 Trier, Germany.
Frank HartmannDepartment of Hematology and Oncology, Hospital Lippe, 32657 Lippe, Germany.
Jan M MiddekeDepartment of Internal Medicine I, University Hospital Dresden, Technical University Dresden, 01307 Dresden, Germany.
Christoph RölligDepartment of Internal Medicine I, University Hospital Dresden, Technical University Dresden, 01307 Dresden, Germany.ORCID 0000-0002-3791-0548
Hartmut DöhnerDepartment of Internal Medicine III, University Hospital of Ulm, 89081 Ulm, Germany.
Konstanze DöhnerDepartment of Internal Medicine III, University Hospital of Ulm, 89081 Ulm, Germany.
Gernot BeutelDepartment of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany.
Felicitas R TholDepartment of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany.ORCID 0000-0001-5848-6152
Florian H HeidelDepartment of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany.
Michael HeuserDepartment of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany.
Rabia ShahswarDepartment of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, 30625 Hannover, Germany.ORCID 0000-0001-6266-6316

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD) before treatment and renal function decline during treatment are common in elderly patients receiving hypomethylating agents (HMAs) and venetoclax (VEN). This retrospective multicenter study of 130 newly diagnosed older acute myeloid leukemia (AML) patients evaluated the prognostic impact of renal function before and during the first treatment cycle. A total of 56 patients (43%) had CKD, and 49 (38%) developed acute kidney injury (AKI) during treatment. AKI occurrence was associated with laboratory tumor lysis syndrome (LTLS). CKD before treatment showed a trend towards a lower overall response rate (ORR, OR 0.5,

Indexed as

acute kidney injuryacute myeloid leukemiachronic kidney diseasetreatment outcomesvenetoclax

Identifiers

PMID41008838
PMCPMC12468355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.